http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 06 Aug 2026 04:11:18 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html <p>Harbour BioMed (HKEX: 02142) has appointed Dr. Bob Zhang as President of its Metabolic Disease Franchise, the company announced. Dr. Zhang will be based in Shanghai and report directly to Dr. Jingsong Wang, Founder, Chairman and Chief Executive Officer.</p> <p>In his new role, Dr. Zhang will oversee portfolio development, research and development, strategic collaborations, and organizational growth within the franchise, which focuses on obesity, metabolic diseases, metabolic dysfunction-associated steatohepatitis (MASH), liver diseases, and cardiovascular disorders.</p> <p>Dr. Zhang brings more than 20 years of experience in metabolic and liver disease research and development. Before joining Harbour BioMed, he served as Co-founder and Chief http://www.streetinsider.com/Management+Changes/Harbour+BioMed+names+Bob+Zhang+to+lead+metabolic+disease+franchise/26876949.html Thu, 06 Aug 2026 04:11:18 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>Aug. 6, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced the appointment of Dr. <person>Bob Zhang</person> as President of Metabolic Disease Franchise. <person>Dr. Zhang</person> will be based in <location value="LU/cn..shangh" idsrc="xmltag.org" >Shanghai</location> and report directly to Dr. <person>Jingsong Wang</person>, Founder, Chairman and Chief Executive Officer of Harbour BioMed.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Harbour+BioMed+Appoints+Dr.+Bob+Zhang+as+President+of+Metabolic+Disease+Franchise+to+Accelerate+Global+Development+of+Innovative+Therapies/26876948.html Thu, 06 Aug 2026 04:10:00 -0400 02142 2142 6XY A.00757254 A.20576704 O.04877439 O.28497952 O.34279193 http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.ma.cambri" idsrc="xmltag.org" >CAMBRIDGE, Mass.</location>, <location value="LU/nl..rotter" idsrc="xmltag.org" >ROTTERDAM, Netherlands</location> and <location value="LU/cn..shangh" idsrc="xmltag.org" >SHANGHAI</location></span>, <span class="legendSpanClass"><chron>July 27, 2026</chron></span> /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that it has entered into a strategic collaboration with <span>China National Pharmaceutical Group Co., Ltd.</span> ("Sino<span id="spanHghlt16e1">pharm</span><span id="spanHghlt57e6">"</span>). The two parties will establish the Sino<span id="spanHghlt2cda">pharm</span> - Harbour BioMed <span id="spanHghlt2b84">Innova</span>tion Consortium (the "<span id="spanHghlt0fa5">Inno</span>vation Consortium") to advance collaborative research and development of innovative biologics.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Harbour+BioMed+and+Sinopharm+Enter+Strategic+Collaboration+to+Establish+Innovation+R%26amp%3BD+Consortium/26815198.html Mon, 27 Jul 2026 05:02:00 -0400 02142 2142 6XY A.19193785 O.27286523 O.34279193